Spring til...

  • Hovedindhold
  • Indholdsfortegnelse
  • Sidefod
  • English en
Videnskabelig artikel 16. MAJ 2024

Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis.

Udgivelsens forfattere:

  • Jon Lykkegaard Andersen
  • Jakob Sidenius Johansen
  • Edyta Maria Urbanska
  • Peter Meldgaard
  • Peter Hjorth-Hansen
  • Charlotte Kristensen
  • Miroslaw Stelmach
  • Eric Santoni-Rugiu
  • Maiken Parm Ulhøi
  • Betina Højgaard
  • Morten Sall Jensen
  • Anders Bondo Dydensborg
  • Christina Dünweber
  • Karin Holmskov Hansen
Download udgivelsen
Download udgivelsen
Aim: The main purpose of the present study was to investigate the labor market affiliation of ALK+ NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Materials & methods: Nationwide retrospective study of all patients with ALK+ NSCLC in Denmark diagnosed between 2012 and 2018. Results: During the study period ALK+ NSCLC patients had a median overall survival of 44.0 months and a 7.8-fold increase in disease prevalence. Six months prior to diagnosis, 81% of ALK+ NSCLC patients ≤60 years of age were employed. At the end of the 18-month follow-up period, 36% were employed. Conclusion: ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market.

Udgivelsens forfattere

  • Jon Lykkegaard AndersenJakob Sidenius JohansenEdyta Maria UrbanskaPeter MeldgaardPeter Hjorth-HansenCharlotte KristensenMiroslaw StelmachEric Santoni-RugiuMaiken Parm UlhøiBetina HøjgaardMorten Sall JensenAnders Bondo DydensborgChristina DünweberKarin Holmskov Hansen

Om denne udgivelse

  • Publiceret i

    Lung Cancer Management
Det Nationale Forsknings- og Analysecenter for Velfærd leverer viden, der bidrager til at udvikle velfærdssamfundet og til at styrke kvalitetsudvikling, effektivisering og styring i den offentlige sektor både i kommuner, regioner og nationalt.

Tilmeld dig vores nyhedsbrev

Få vores nyeste viden serveret i din indbakke - hver uge!

Nyhedsbrev
Tlf: 44 45 55 00
Mail: vive@vive.dk
EAN: 5798000354845
CVR: 23 15 51 17
  • Nyheder og debat
  • Presse
  • Kontakt
  • Ledige stillinger
  • Tilgængelighedserklæring

Tilmeld dig vores nyhedsbrev

Få vores nyeste viden serveret i din indbakke - hver uge!

Nyhedsbrev